AnaptysBio (NASDAQ:ANAB) received a $147.00 price objective from analysts at Credit Suisse Group in a report issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 49.53% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald set a $124.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a report on Saturday, September 22nd. Wedbush reissued an “outperform” rating and issued a $138.00 price target on shares of AnaptysBio in a report on Tuesday, September 18th. Stifel Nicolaus set a $127.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a report on Friday, September 14th. JMP Securities cut their price target on shares of AnaptysBio from $180.00 to $153.00 and set a “buy” rating on the stock in a report on Wednesday, August 15th. Finally, Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. AnaptysBio has an average rating of “Buy” and an average target price of $129.30.

Shares of NASDAQ:ANAB traded down $1.83 during midday trading on Thursday, reaching $98.31. The company had a trading volume of 634 shares, compared to its average volume of 414,828. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.19 and a current ratio of 16.19. The company has a market capitalization of $2.27 billion, a P/E ratio of -66.19 and a beta of 2.81. AnaptysBio has a 52-week low of $33.76 and a 52-week high of $134.00.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13. research analysts predict that AnaptysBio will post -2.69 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANAB. Janus Henderson Group PLC lifted its holdings in AnaptysBio by 45.3% during the second quarter. Janus Henderson Group PLC now owns 2,830,322 shares of the biotechnology company’s stock valued at $201,066,000 after purchasing an additional 882,440 shares during the last quarter. Redmile Group LLC lifted its holdings in AnaptysBio by 127.6% during the first quarter. Redmile Group LLC now owns 523,150 shares of the biotechnology company’s stock valued at $54,449,000 after purchasing an additional 293,300 shares during the last quarter. Millennium Management LLC lifted its holdings in AnaptysBio by 73.1% during the first quarter. Millennium Management LLC now owns 309,461 shares of the biotechnology company’s stock valued at $32,209,000 after purchasing an additional 130,686 shares during the last quarter. Partner Fund Management L.P. lifted its holdings in AnaptysBio by 96.6% during the second quarter. Partner Fund Management L.P. now owns 138,338 shares of the biotechnology company’s stock valued at $9,828,000 after purchasing an additional 67,984 shares during the last quarter. Finally, OppenheimerFunds Inc. lifted its holdings in AnaptysBio by 5.2% during the second quarter. OppenheimerFunds Inc. now owns 1,101,887 shares of the biotechnology company’s stock valued at $78,278,000 after purchasing an additional 54,773 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

See Also: How can investors find ex-dividend dates?

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.